Neuren Pharmaceuticals Limited (NURPF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD

Add to watchlist

14.00

0.00

(0.00%)

At close: 09:44AM EDT

Loading interactive chart…

Simply Wall St.
Are Investors Undervaluing Neuren Pharmaceuticals Limited (ASX:NEU) By 46%?
Key Insights Neuren Pharmaceuticals' estimated fair value is AU$37.87 based on 2 Stage Free Cash Flow to Equity Current...
PR Newswire
Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as
Simply Wall St.
Are Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock?
Most readers would already be aware that Neuren Pharmaceuticals' (ASX:NEU) stock increased significantly by 22% over...